- Home
- XFOR vs CLLS Comparison
XFOR vs CLLS Comparison
Compare XFOR & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XFOR | CLLS |
|---|---|---|
| Founded | 2014 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 332.3M | 299.0M |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | XFOR | CLLS |
|---|---|---|
| Price | $3.93 | $5.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $28.50 | $8.00 |
| AVG Volume (30 Days) | ★ 603.4K | 138.4K |
| Earning Date | 11-05-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $33,979,000.00 | ★ $82,551,000.00 |
| Revenue This Year | $1,276.65 | $32.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2925.74 | 129.04 |
| 52 Week Low | $1.35 | $1.10 |
| 52 Week High | $26.83 | $5.48 |
Technical Indicators
Market Signals| Indicator | XFOR | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 55.65 | 65.75 |
| Support Level | $3.53 | $4.47 |
| Resistance Level | $4.07 | $4.90 |
| Average True Range (ATR) | 0.28 | 0.28 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 80.88 | 76.53 |
Price Performance
Historical ComparisonAbout XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.